Global Long-Acting Asthma Biologic Market Growth (Status and Outlook) 2026-2032
The global Long-Acting Asthma Biologic market size is predicted to grow from US$ 9042 million in 2025 to US$ 17711 million in 2032; it is expected to grow at a CAGR of 9.9% from 2026 to 2032.
Long-Acting Asthma Biologic refers to biologic therapies used as scheduled add-on maintenance treatment for patients with moderate-to-severe or severe asthma who remain inadequately controlled with conventional controller therapy. The market primarily covers marketed monoclonal antibodies targeting key inflammatory pathways such as IgE, IL-5, IL-5R?, IL-4R? and TSLP, with treatment selection increasingly guided by eosinophil levels, allergic status, Type 2 inflammatory characteristics and other clinical biomarkers. Products are delivered mainly by subcutaneous injection, with intravenous administration used for selected therapies, and dosing schedules range from biweekly or monthly administration to extended maintenance intervals of eight weeks or six months. The core value proposition of Long-Acting Asthma Biologics is to reduce severe exacerbations, improve long-term asthma control, lower dependence on systemic corticosteroids in appropriate patients and reduce treatment burden through sustained pharmacological activity and less frequent administration. The study focuses on commercially marketed biologics used for long-term asthma maintenance and evaluates the market by therapeutic target, dosing interval, asthma phenotype, dosing strategy and downstream treatment setting. The recent commercialization of twice-yearly depemokimab has further extended the technological boundary of long-acting asthma therapy and established a new reference point for dosing convenience.
Key Findings
Twice-yearly dosing establishes a new benchmark for long-acting asthma biologics
Anti-IL-5 pathways remain central to eosinophilic severe asthma treatment
Eight-week maintenance dosing differentiates benralizumab from monthly biologic regimens
Self-administration is shifting selected biologic therapy toward home settings
China’s marketed domestic biologics currently concentrate on anti-IgE therapy
Market Trends
The Long-Acting Asthma Biologic market is moving from simple target differentiation toward a combination of longer dosing intervals, broader phenotype coverage and more convenient drug-delivery formats. Earlier biologics established two- to four-week dosing as the conventional maintenance pattern, while benralizumab extended maintenance treatment to every eight weeks after initial loading doses. The launch of depemokimab has moved the dosing frontier further to once every six months, strengthening the commercial importance of treatment persistence and administration convenience. At the same time, prefilled syringes, pens and approved self-administration are moving part of biologic treatment from specialist clinics toward the home, reducing repeated facility visits for appropriate patients. Tezepelumab is another important structural development because upstream TSLP inhibition broadens the addressable severe-asthma population beyond narrowly defined eosinophilic or allergic phenotypes. As more mechanisms become commercially established, future product differentiation is increasingly likely to depend on dosing frequency, ease of administration, phenotype coverage, corticosteroid-sparing potential, treatment persistence and payer accessibility rather than target novelty alone.
Market Dynamics
Drivers
Demand for Long-Acting Asthma Biologics is primarily supported by the persistent unmet need among patients whose disease remains inadequately controlled despite high-dose inhaled corticosteroids and additional controller therapy. Severe exacerbations, repeated systemic corticosteroid exposure and the long-term burden of poorly controlled asthma create a strong clinical rationale for targeted maintenance biologics. Extended dosing intervals add another demand driver by reducing injection frequency and treatment-related inconvenience. The movement from clinic-only administration toward prefilled syringes, autoinjectors and qualified home administration further improves treatment accessibility and may support persistence in long-term therapy.
Restraints
The main restraints arise from the high treatment cost of biologic therapy, reimbursement and prior-authorization requirements, and the need to identify appropriate patients through specialist evaluation and biomarker-based treatment pathways. Clinical response can vary materially among individuals, while switching between different mechanisms is not always straightforward because asthma phenotypes may overlap and evolve over time. In addition, biologics are maintenance therapies rather than rescue treatments, which limits their use to clearly defined patient populations and requires continued background asthma management. As multiple established products compete for similar severe-asthma populations, payer scrutiny of incremental clinical benefit and dosing convenience is also becoming more important.
Opportunities
The strongest market opportunity is shifting toward therapies that can preserve clinical control while materially reducing administration frequency. Patients currently treated every two or four weeks represent a potential population for longer-interval options when clinical characteristics and treatment eligibility are appropriate. Additional opportunities are emerging from self-administration, simplified fixed-dose formats and expansion into severe-asthma populations that are not easily classified by a single downstream biomarker. Upstream inflammatory targets such as TSLP have already demonstrated the commercial potential of broader phenotype positioning, while six-month dosing establishes a new product-development and lifecycle-management benchmark for the category.
Challenges
The industry faces increasing difficulty in demonstrating meaningful differentiation as the number of approved asthma biologic mechanisms grows. A new product must increasingly compete not only on exacerbation reduction and safety but also on dosing interval, administration device, eligible patient breadth, corticosteroid-sparing evidence, real-world persistence and reimbursement positioning. Long-term commercial performance also depends on physician confidence in patient selection and switching strategies. In more mature targets, particularly anti-IgE, biosimilar and domestically produced alternatives may gradually strengthen price competition, while premium-priced innovative biologics will need to demonstrate sufficient incremental value to obtain broad reimbursement and formulary access.
Industry Chain Analysis
The upstream industry chain of Long-Acting Asthma Biologics includes monoclonal-antibody cell-line and expression technologies, cell-culture media, bioreactor systems, purification resins, filtration materials, pharmaceutical excipients, sterile packaging components, prefilled syringes and autoinjector components. Compared with conventional small-molecule asthma drugs, manufacturing requires substantially more complex biologic production, purification, aseptic filling, quality-control and cold-chain capabilities. Longer-acting products may also require antibody engineering and pharmacokinetic optimization to extend systemic exposure while maintaining biological activity and acceptable safety.
The midstream segment covers commercial monoclonal-antibody drug-substance manufacturing, purification, formulation, fill-finish, device integration, batch release and regulatory quality management. Downstream commercialization primarily passes through respiratory and allergy specialists, hospitals, specialty treatment centers, specialty pharmacies and reimbursement systems, with selected products increasingly supporting patient or caregiver administration at home. Value creation is concentrated in target validation, durable efficacy, dosing-interval extension, reliable biologic manufacturing, user-friendly delivery devices and market access. Consequently, the competitive value of a product is determined not simply by manufacturing cost but by the combination of clinical differentiation, administration convenience, treatment persistence and reimbursement acceptance.
Segment Insights
By therapeutic target, anti-IL-5 and anti-IL-5R? products form one of the most important segments of the Long-Acting Asthma Biologic market because eosinophilic severe asthma provides a clearly identifiable patient population and because this pathway currently contains both monthly, eight-week and six-month commercial dosing strategies. Mepolizumab is administered every four weeks, benralizumab transitions to every eight weeks after initial dosing, and depemokimab has extended anti-IL-5 maintenance treatment to once every six months. This makes the IL-5 pathway particularly important in the industry's transition from conventional biologic therapy toward genuinely extended-interval products.
Anti-IgE, anti-IL-4R? and anti-TSLP therapies provide differentiated positioning across allergic asthma, Type 2 inflammation and broader severe-asthma populations. Omalizumab uses an IgE- and body-weight-related dosing strategy and is administered every two or four weeks, while tezepelumab uses a fixed subcutaneous dose every four weeks and offers relatively broad phenotype coverage. From a dosing-interval perspective, these products are less extended than the newest ultra-long-acting biologics, but they remain important parts of the wider long-term asthma biologic treatment landscape and provide competitive reference points for future long-interval products.
Downstream Market Opportunities
The principal downstream opportunity remains patients with severe or difficult-to-control asthma managed by respiratory specialists and allergy specialists, particularly patients experiencing recurrent exacerbations despite optimized inhaled maintenance therapy. The commercial opportunity is increasingly shifting from simply increasing biologic eligibility toward improving treatment continuity and reducing administration burden. Long-interval products are particularly relevant for patients for whom frequent clinic attendance or repeated injections create adherence barriers, while self-administration formats provide additional opportunities in home-based chronic disease management. Broader biomarker positioning can also expand biologic use among severe-asthma patients who do not fit traditional allergic or highly eosinophilic profiles, supporting a gradual move toward more individualized biologic selection.
Regional Insights
North America and Europe represent highly developed markets for asthma biologic therapy, supported by established specialist treatment pathways and access to multiple commercial mechanisms. The United States added depemokimab to the marketed treatment landscape in December 2025, while the European Union granted marketing authorization in February 2026. Its once-every-six-months administration has introduced an ultra-long-acting commercial option into both regions and provides a new benchmark against established two-week, four-week and eight-week regimens. Europe also has an established commercial portfolio spanning omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab, creating a comparatively mature environment for mechanism-based treatment selection.
China is developing along a somewhat different path, with local commercial participation currently more visible in the anti-IgE segment. Mabpharm's CMAB007 omalizumab ? was approved in 2023 for IgE-mediated asthma, while CSPC's commercial portfolio includes an omalizumab biosimilar for moderate-to-severe persistent allergic asthma. This structure suggests that China's near-term market development will be influenced simultaneously by greater availability of domestically produced established-target biologics and by the longer-term adoption of differentiated long-interval therapies.
Competitive Landscape Analysis
Competition in Long-Acting Asthma Biologics is evolving from target-based competition toward multidimensional differentiation. Established products occupy distinct positions across IgE, IL-5, IL-5R?, IL-4R? and TSLP pathways, creating a market in which physicians can increasingly match biologic mechanisms to asthma phenotype, biomarkers and prior treatment response. GSK has strengthened its position in the IL-5 pathway through the coexistence of monthly mepolizumab and twice-yearly depemokimab, while AstraZeneca participates through eight-week maintenance benralizumab and four-week tezepelumab, the latter commercialized with Amgen involvement. Omalizumab remains an established anti-IgE reference therapy, while dupilumab and tezepelumab broaden competitive positioning into Type 2 and wider severe-asthma populations. The emergence of domestically produced omalizumab products in China adds a second competitive dimension around affordability and local supply. Going forward, competitive advantage is likely to depend increasingly on the combined performance of clinical efficacy, dosing interval, eligible patient breadth, administration convenience, real-world persistence and reimbursement access rather than on mechanism of action alone.
Report Scope
LPI (LP Information)' newest research report, the “Long-Acting Asthma Biologic Industry Forecast” looks at past sales and reviews total world Long-Acting Asthma Biologic sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-Acting Asthma Biologic sales for 2026 through 2032. With Long-Acting Asthma Biologic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-Acting Asthma Biologic industry.
This Insight Report provides a comprehensive analysis of the global Long-Acting Asthma Biologic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Long-Acting Asthma Biologic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-Acting Asthma Biologic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-Acting Asthma Biologic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-Acting Asthma Biologic.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-Acting Asthma Biologic market by product type, application, key players and key regions and countries.
Market Segmentation
Long-Acting Asthma Biologic refers to biologic therapies used as scheduled add-on maintenance treatment for patients with moderate-to-severe or severe asthma who remain inadequately controlled with conventional controller therapy. The market primarily covers marketed monoclonal antibodies targeting key inflammatory pathways such as IgE, IL-5, IL-5R?, IL-4R? and TSLP, with treatment selection increasingly guided by eosinophil levels, allergic status, Type 2 inflammatory characteristics and other clinical biomarkers. Products are delivered mainly by subcutaneous injection, with intravenous administration used for selected therapies, and dosing schedules range from biweekly or monthly administration to extended maintenance intervals of eight weeks or six months. The core value proposition of Long-Acting Asthma Biologics is to reduce severe exacerbations, improve long-term asthma control, lower dependence on systemic corticosteroids in appropriate patients and reduce treatment burden through sustained pharmacological activity and less frequent administration. The study focuses on commercially marketed biologics used for long-term asthma maintenance and evaluates the market by therapeutic target, dosing interval, asthma phenotype, dosing strategy and downstream treatment setting. The recent commercialization of twice-yearly depemokimab has further extended the technological boundary of long-acting asthma therapy and established a new reference point for dosing convenience.
Key Findings
Twice-yearly dosing establishes a new benchmark for long-acting asthma biologics
Anti-IL-5 pathways remain central to eosinophilic severe asthma treatment
Eight-week maintenance dosing differentiates benralizumab from monthly biologic regimens
Self-administration is shifting selected biologic therapy toward home settings
China’s marketed domestic biologics currently concentrate on anti-IgE therapy
Market Trends
The Long-Acting Asthma Biologic market is moving from simple target differentiation toward a combination of longer dosing intervals, broader phenotype coverage and more convenient drug-delivery formats. Earlier biologics established two- to four-week dosing as the conventional maintenance pattern, while benralizumab extended maintenance treatment to every eight weeks after initial loading doses. The launch of depemokimab has moved the dosing frontier further to once every six months, strengthening the commercial importance of treatment persistence and administration convenience. At the same time, prefilled syringes, pens and approved self-administration are moving part of biologic treatment from specialist clinics toward the home, reducing repeated facility visits for appropriate patients. Tezepelumab is another important structural development because upstream TSLP inhibition broadens the addressable severe-asthma population beyond narrowly defined eosinophilic or allergic phenotypes. As more mechanisms become commercially established, future product differentiation is increasingly likely to depend on dosing frequency, ease of administration, phenotype coverage, corticosteroid-sparing potential, treatment persistence and payer accessibility rather than target novelty alone.
Market Dynamics
Drivers
Demand for Long-Acting Asthma Biologics is primarily supported by the persistent unmet need among patients whose disease remains inadequately controlled despite high-dose inhaled corticosteroids and additional controller therapy. Severe exacerbations, repeated systemic corticosteroid exposure and the long-term burden of poorly controlled asthma create a strong clinical rationale for targeted maintenance biologics. Extended dosing intervals add another demand driver by reducing injection frequency and treatment-related inconvenience. The movement from clinic-only administration toward prefilled syringes, autoinjectors and qualified home administration further improves treatment accessibility and may support persistence in long-term therapy.
Restraints
The main restraints arise from the high treatment cost of biologic therapy, reimbursement and prior-authorization requirements, and the need to identify appropriate patients through specialist evaluation and biomarker-based treatment pathways. Clinical response can vary materially among individuals, while switching between different mechanisms is not always straightforward because asthma phenotypes may overlap and evolve over time. In addition, biologics are maintenance therapies rather than rescue treatments, which limits their use to clearly defined patient populations and requires continued background asthma management. As multiple established products compete for similar severe-asthma populations, payer scrutiny of incremental clinical benefit and dosing convenience is also becoming more important.
Opportunities
The strongest market opportunity is shifting toward therapies that can preserve clinical control while materially reducing administration frequency. Patients currently treated every two or four weeks represent a potential population for longer-interval options when clinical characteristics and treatment eligibility are appropriate. Additional opportunities are emerging from self-administration, simplified fixed-dose formats and expansion into severe-asthma populations that are not easily classified by a single downstream biomarker. Upstream inflammatory targets such as TSLP have already demonstrated the commercial potential of broader phenotype positioning, while six-month dosing establishes a new product-development and lifecycle-management benchmark for the category.
Challenges
The industry faces increasing difficulty in demonstrating meaningful differentiation as the number of approved asthma biologic mechanisms grows. A new product must increasingly compete not only on exacerbation reduction and safety but also on dosing interval, administration device, eligible patient breadth, corticosteroid-sparing evidence, real-world persistence and reimbursement positioning. Long-term commercial performance also depends on physician confidence in patient selection and switching strategies. In more mature targets, particularly anti-IgE, biosimilar and domestically produced alternatives may gradually strengthen price competition, while premium-priced innovative biologics will need to demonstrate sufficient incremental value to obtain broad reimbursement and formulary access.
Industry Chain Analysis
The upstream industry chain of Long-Acting Asthma Biologics includes monoclonal-antibody cell-line and expression technologies, cell-culture media, bioreactor systems, purification resins, filtration materials, pharmaceutical excipients, sterile packaging components, prefilled syringes and autoinjector components. Compared with conventional small-molecule asthma drugs, manufacturing requires substantially more complex biologic production, purification, aseptic filling, quality-control and cold-chain capabilities. Longer-acting products may also require antibody engineering and pharmacokinetic optimization to extend systemic exposure while maintaining biological activity and acceptable safety.
The midstream segment covers commercial monoclonal-antibody drug-substance manufacturing, purification, formulation, fill-finish, device integration, batch release and regulatory quality management. Downstream commercialization primarily passes through respiratory and allergy specialists, hospitals, specialty treatment centers, specialty pharmacies and reimbursement systems, with selected products increasingly supporting patient or caregiver administration at home. Value creation is concentrated in target validation, durable efficacy, dosing-interval extension, reliable biologic manufacturing, user-friendly delivery devices and market access. Consequently, the competitive value of a product is determined not simply by manufacturing cost but by the combination of clinical differentiation, administration convenience, treatment persistence and reimbursement acceptance.
Segment Insights
By therapeutic target, anti-IL-5 and anti-IL-5R? products form one of the most important segments of the Long-Acting Asthma Biologic market because eosinophilic severe asthma provides a clearly identifiable patient population and because this pathway currently contains both monthly, eight-week and six-month commercial dosing strategies. Mepolizumab is administered every four weeks, benralizumab transitions to every eight weeks after initial dosing, and depemokimab has extended anti-IL-5 maintenance treatment to once every six months. This makes the IL-5 pathway particularly important in the industry's transition from conventional biologic therapy toward genuinely extended-interval products.
Anti-IgE, anti-IL-4R? and anti-TSLP therapies provide differentiated positioning across allergic asthma, Type 2 inflammation and broader severe-asthma populations. Omalizumab uses an IgE- and body-weight-related dosing strategy and is administered every two or four weeks, while tezepelumab uses a fixed subcutaneous dose every four weeks and offers relatively broad phenotype coverage. From a dosing-interval perspective, these products are less extended than the newest ultra-long-acting biologics, but they remain important parts of the wider long-term asthma biologic treatment landscape and provide competitive reference points for future long-interval products.
Downstream Market Opportunities
The principal downstream opportunity remains patients with severe or difficult-to-control asthma managed by respiratory specialists and allergy specialists, particularly patients experiencing recurrent exacerbations despite optimized inhaled maintenance therapy. The commercial opportunity is increasingly shifting from simply increasing biologic eligibility toward improving treatment continuity and reducing administration burden. Long-interval products are particularly relevant for patients for whom frequent clinic attendance or repeated injections create adherence barriers, while self-administration formats provide additional opportunities in home-based chronic disease management. Broader biomarker positioning can also expand biologic use among severe-asthma patients who do not fit traditional allergic or highly eosinophilic profiles, supporting a gradual move toward more individualized biologic selection.
Regional Insights
North America and Europe represent highly developed markets for asthma biologic therapy, supported by established specialist treatment pathways and access to multiple commercial mechanisms. The United States added depemokimab to the marketed treatment landscape in December 2025, while the European Union granted marketing authorization in February 2026. Its once-every-six-months administration has introduced an ultra-long-acting commercial option into both regions and provides a new benchmark against established two-week, four-week and eight-week regimens. Europe also has an established commercial portfolio spanning omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab, creating a comparatively mature environment for mechanism-based treatment selection.
China is developing along a somewhat different path, with local commercial participation currently more visible in the anti-IgE segment. Mabpharm's CMAB007 omalizumab ? was approved in 2023 for IgE-mediated asthma, while CSPC's commercial portfolio includes an omalizumab biosimilar for moderate-to-severe persistent allergic asthma. This structure suggests that China's near-term market development will be influenced simultaneously by greater availability of domestically produced established-target biologics and by the longer-term adoption of differentiated long-interval therapies.
Competitive Landscape Analysis
Competition in Long-Acting Asthma Biologics is evolving from target-based competition toward multidimensional differentiation. Established products occupy distinct positions across IgE, IL-5, IL-5R?, IL-4R? and TSLP pathways, creating a market in which physicians can increasingly match biologic mechanisms to asthma phenotype, biomarkers and prior treatment response. GSK has strengthened its position in the IL-5 pathway through the coexistence of monthly mepolizumab and twice-yearly depemokimab, while AstraZeneca participates through eight-week maintenance benralizumab and four-week tezepelumab, the latter commercialized with Amgen involvement. Omalizumab remains an established anti-IgE reference therapy, while dupilumab and tezepelumab broaden competitive positioning into Type 2 and wider severe-asthma populations. The emergence of domestically produced omalizumab products in China adds a second competitive dimension around affordability and local supply. Going forward, competitive advantage is likely to depend increasingly on the combined performance of clinical efficacy, dosing interval, eligible patient breadth, administration convenience, real-world persistence and reimbursement access rather than on mechanism of action alone.
Report Scope
LPI (LP Information)' newest research report, the “Long-Acting Asthma Biologic Industry Forecast” looks at past sales and reviews total world Long-Acting Asthma Biologic sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-Acting Asthma Biologic sales for 2026 through 2032. With Long-Acting Asthma Biologic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-Acting Asthma Biologic industry.
This Insight Report provides a comprehensive analysis of the global Long-Acting Asthma Biologic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Long-Acting Asthma Biologic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-Acting Asthma Biologic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-Acting Asthma Biologic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-Acting Asthma Biologic.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-Acting Asthma Biologic market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- Ultra-Long-Acting Biologics
- Long-Interval Biologics
- Monthly Biologics
Segmentation by Antibody Types:
- Anti-IL-5 Biologics
- Anti-IL-5R? Biologics
- Anti-IgE Biologics
- Anti-IL-4R? Biologics
- Anti-TSLP Biologics
Segmentation by Drugs Type:
- Depemokimab
- Benralizumab
- Mepolizumab
- Reslizumab
- Tezepelumab
- Omalizumab
- Dupilumab
Segmentation by Application:
- evere Eosinophilic Asthma
- Moderate-to-Severe Allergic Asthma
- Severe Type 2 Asthma
- Other
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GSK
- AstraZeneca
- Amgen
- Novartis
- Roche Holding
- Sanofi
- Regeneron Pharmaceuticals
- Teva Pharmaceutical
- Mabpharm Limited
- CSPC Pharmaceutical
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-Acting Asthma Biologic Market Size (2021-2032)
2.1.2 Long-Acting Asthma Biologic Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Long-Acting Asthma Biologic by Country/Region (2021, 2025 & 2032)
2.2 Long-Acting Asthma Biologic Segment by Type
2.2.1 Ultra-Long-Acting Biologics
2.2.2 Long-Interval Biologics
2.2.3 Monthly Biologics
2.2.4 Long-Acting Asthma Biologic Market Size by Type
2.2.4.1 Long-Acting Asthma Biologic Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
2.3 Long-Acting Asthma Biologic Segment by Antibody Types
2.3.1 Anti-IL-5 Biologics
2.3.2 Anti-IL-5R? Biologics
2.3.3 Anti-IgE Biologics
2.3.4 Anti-IL-4R? Biologics
2.3.5 Anti-TSLP Biologics
2.3.6 Long-Acting Asthma Biologic Market Size by Antibody Types
2.3.6.1 Long-Acting Asthma Biologic Market Size CAGR by Antibody Types (2021 VS 2025 VS 2032)
2.3.6.2 Global Long-Acting Asthma Biologic Market Size Market Share by Antibody Types (2021-2026)
2.4 Long-Acting Asthma Biologic Segment by Drugs Type
2.4.1 Depemokimab
2.4.2 Benralizumab
2.4.3 Mepolizumab
2.4.4 Reslizumab
2.4.5 Tezepelumab
2.4.6 Omalizumab
2.4.7 Dupilumab
2.4.8 Long-Acting Asthma Biologic Market Size by Drugs Type
2.4.8.1 Long-Acting Asthma Biologic Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032)
2.4.8.2 Global Long-Acting Asthma Biologic Market Size Market Share by Drugs Type (2021-2026)
2.5 Long-Acting Asthma Biologic Segment by Application
2.5.1 evere Eosinophilic Asthma
2.5.2 Moderate-to-Severe Allergic Asthma
2.5.3 Severe Type 2 Asthma
2.5.4 Other
2.5.5 Long-Acting Asthma Biologic Market Size by Application
2.5.5.1 Long-Acting Asthma Biologic Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.5.2 Global Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
3 LONG-ACTING ASTHMA BIOLOGIC MARKET SIZE BY PLAYER
3.1 Long-Acting Asthma Biologic Market Size Market Share by Player
3.1.1 Global Long-Acting Asthma Biologic Revenue by Player (2021-2026)
3.1.2 Global Long-Acting Asthma Biologic Revenue Market Share by Player (2021-2026)
3.2 Global Long-Acting Asthma Biologic Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 LONG-ACTING ASTHMA BIOLOGIC BY REGION
4.1 Long-Acting Asthma Biologic Market Size by Region (2021-2026)
4.2 Global Long-Acting Asthma Biologic Annual Revenue by Country/Region (2021-2026)
4.3 Americas Long-Acting Asthma Biologic Market Size Growth (2021-2026)
4.4 APAC Long-Acting Asthma Biologic Market Size Growth (2021-2026)
4.5 Europe Long-Acting Asthma Biologic Market Size Growth (2021-2026)
4.6 Middle East & Africa Long-Acting Asthma Biologic Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Long-Acting Asthma Biologic Market Size by Country (2021-2026)
5.2 Americas Long-Acting Asthma Biologic Market Size by Type (2021-2026)
5.3 Americas Long-Acting Asthma Biologic Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-Acting Asthma Biologic Market Size by Region (2021-2026)
6.2 APAC Long-Acting Asthma Biologic Market Size by Type (2021-2026)
6.3 APAC Long-Acting Asthma Biologic Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Long-Acting Asthma Biologic Market Size by Country (2021-2026)
7.2 Europe Long-Acting Asthma Biologic Market Size by Type (2021-2026)
7.3 Europe Long-Acting Asthma Biologic Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-Acting Asthma Biologic by Region (2021-2026)
8.2 Middle East & Africa Long-Acting Asthma Biologic Market Size by Type (2021-2026)
8.3 Middle East & Africa Long-Acting Asthma Biologic Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL LONG-ACTING ASTHMA BIOLOGIC MARKET FORECAST
10.1 Global Long-Acting Asthma Biologic Forecast by Region (2027-2032)
10.1.1 Global Long-Acting Asthma Biologic Forecast by Region (2027-2032)
10.1.2 Americas Long-Acting Asthma Biologic Forecast
10.1.3 APAC Long-Acting Asthma Biologic Forecast
10.1.4 Europe Long-Acting Asthma Biologic Forecast
10.1.5 Middle East & Africa Long-Acting Asthma Biologic Forecast
10.2 Americas Long-Acting Asthma Biologic Forecast by Country (2027-2032)
10.2.1 United States Market Long-Acting Asthma Biologic Forecast
10.2.2 Canada Market Long-Acting Asthma Biologic Forecast
10.2.3 Mexico Market Long-Acting Asthma Biologic Forecast
10.2.4 Brazil Market Long-Acting Asthma Biologic Forecast
10.3 APAC Long-Acting Asthma Biologic Forecast by Region (2027-2032)
10.3.1 China Long-Acting Asthma Biologic Market Forecast
10.3.2 Japan Market Long-Acting Asthma Biologic Forecast
10.3.3 Korea Market Long-Acting Asthma Biologic Forecast
10.3.4 Southeast Asia Market Long-Acting Asthma Biologic Forecast
10.3.5 India Market Long-Acting Asthma Biologic Forecast
10.3.6 Australia Market Long-Acting Asthma Biologic Forecast
10.4 Europe Long-Acting Asthma Biologic Forecast by Country (2027-2032)
10.4.1 Germany Market Long-Acting Asthma Biologic Forecast
10.4.2 France Market Long-Acting Asthma Biologic Forecast
10.4.3 UK Market Long-Acting Asthma Biologic Forecast
10.4.4 Italy Market Long-Acting Asthma Biologic Forecast
10.4.5 Russia Market Long-Acting Asthma Biologic Forecast
10.5 Middle East & Africa Long-Acting Asthma Biologic Forecast by Region (2027-2032)
10.5.1 Egypt Market Long-Acting Asthma Biologic Forecast
10.5.2 South Africa Market Long-Acting Asthma Biologic Forecast
10.5.3 Israel Market Long-Acting Asthma Biologic Forecast
10.5.4 Turkey Market Long-Acting Asthma Biologic Forecast
10.6 Global Long-Acting Asthma Biologic Forecast by Type (2027-2032)
10.7 Global Long-Acting Asthma Biologic Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Long-Acting Asthma Biologic Forecast
11 KEY PLAYERS ANALYSIS
11.1 GSK
11.1.1 GSK Company Information
11.1.2 GSK Long-Acting Asthma Biologic Product Offered
11.1.3 GSK Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 GSK Main Business Overview
11.1.5 GSK Latest Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Long-Acting Asthma Biologic Product Offered
11.2.3 AstraZeneca Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 AstraZeneca Main Business Overview
11.2.5 AstraZeneca Latest Developments
11.3 Amgen
11.3.1 Amgen Company Information
11.3.2 Amgen Long-Acting Asthma Biologic Product Offered
11.3.3 Amgen Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Amgen Main Business Overview
11.3.5 Amgen Latest Developments
11.4 Novartis
11.4.1 Novartis Company Information
11.4.2 Novartis Long-Acting Asthma Biologic Product Offered
11.4.3 Novartis Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Novartis Main Business Overview
11.4.5 Novartis Latest Developments
11.5 Roche Holding
11.5.1 Roche Holding Company Information
11.5.2 Roche Holding Long-Acting Asthma Biologic Product Offered
11.5.3 Roche Holding Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Roche Holding Main Business Overview
11.5.5 Roche Holding Latest Developments
11.6 Sanofi
11.6.1 Sanofi Company Information
11.6.2 Sanofi Long-Acting Asthma Biologic Product Offered
11.6.3 Sanofi Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sanofi Main Business Overview
11.6.5 Sanofi Latest Developments
11.7 Regeneron Pharmaceuticals
11.7.1 Regeneron Pharmaceuticals Company Information
11.7.2 Regeneron Pharmaceuticals Long-Acting Asthma Biologic Product Offered
11.7.3 Regeneron Pharmaceuticals Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Regeneron Pharmaceuticals Main Business Overview
11.7.5 Regeneron Pharmaceuticals Latest Developments
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Company Information
11.8.2 Teva Pharmaceutical Long-Acting Asthma Biologic Product Offered
11.8.3 Teva Pharmaceutical Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Teva Pharmaceutical Main Business Overview
11.8.5 Teva Pharmaceutical Latest Developments
11.9 Mabpharm Limited
11.9.1 Mabpharm Limited Company Information
11.9.2 Mabpharm Limited Long-Acting Asthma Biologic Product Offered
11.9.3 Mabpharm Limited Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Mabpharm Limited Main Business Overview
11.9.5 Mabpharm Limited Latest Developments
11.10 CSPC Pharmaceutical
11.10.1 CSPC Pharmaceutical Company Information
11.10.2 CSPC Pharmaceutical Long-Acting Asthma Biologic Product Offered
11.10.3 CSPC Pharmaceutical Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 CSPC Pharmaceutical Main Business Overview
11.10.5 CSPC Pharmaceutical Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-Acting Asthma Biologic Market Size (2021-2032)
2.1.2 Long-Acting Asthma Biologic Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Long-Acting Asthma Biologic by Country/Region (2021, 2025 & 2032)
2.2 Long-Acting Asthma Biologic Segment by Type
2.2.1 Ultra-Long-Acting Biologics
2.2.2 Long-Interval Biologics
2.2.3 Monthly Biologics
2.2.4 Long-Acting Asthma Biologic Market Size by Type
2.2.4.1 Long-Acting Asthma Biologic Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
2.3 Long-Acting Asthma Biologic Segment by Antibody Types
2.3.1 Anti-IL-5 Biologics
2.3.2 Anti-IL-5R? Biologics
2.3.3 Anti-IgE Biologics
2.3.4 Anti-IL-4R? Biologics
2.3.5 Anti-TSLP Biologics
2.3.6 Long-Acting Asthma Biologic Market Size by Antibody Types
2.3.6.1 Long-Acting Asthma Biologic Market Size CAGR by Antibody Types (2021 VS 2025 VS 2032)
2.3.6.2 Global Long-Acting Asthma Biologic Market Size Market Share by Antibody Types (2021-2026)
2.4 Long-Acting Asthma Biologic Segment by Drugs Type
2.4.1 Depemokimab
2.4.2 Benralizumab
2.4.3 Mepolizumab
2.4.4 Reslizumab
2.4.5 Tezepelumab
2.4.6 Omalizumab
2.4.7 Dupilumab
2.4.8 Long-Acting Asthma Biologic Market Size by Drugs Type
2.4.8.1 Long-Acting Asthma Biologic Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032)
2.4.8.2 Global Long-Acting Asthma Biologic Market Size Market Share by Drugs Type (2021-2026)
2.5 Long-Acting Asthma Biologic Segment by Application
2.5.1 evere Eosinophilic Asthma
2.5.2 Moderate-to-Severe Allergic Asthma
2.5.3 Severe Type 2 Asthma
2.5.4 Other
2.5.5 Long-Acting Asthma Biologic Market Size by Application
2.5.5.1 Long-Acting Asthma Biologic Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.5.2 Global Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
3 LONG-ACTING ASTHMA BIOLOGIC MARKET SIZE BY PLAYER
3.1 Long-Acting Asthma Biologic Market Size Market Share by Player
3.1.1 Global Long-Acting Asthma Biologic Revenue by Player (2021-2026)
3.1.2 Global Long-Acting Asthma Biologic Revenue Market Share by Player (2021-2026)
3.2 Global Long-Acting Asthma Biologic Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 LONG-ACTING ASTHMA BIOLOGIC BY REGION
4.1 Long-Acting Asthma Biologic Market Size by Region (2021-2026)
4.2 Global Long-Acting Asthma Biologic Annual Revenue by Country/Region (2021-2026)
4.3 Americas Long-Acting Asthma Biologic Market Size Growth (2021-2026)
4.4 APAC Long-Acting Asthma Biologic Market Size Growth (2021-2026)
4.5 Europe Long-Acting Asthma Biologic Market Size Growth (2021-2026)
4.6 Middle East & Africa Long-Acting Asthma Biologic Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Long-Acting Asthma Biologic Market Size by Country (2021-2026)
5.2 Americas Long-Acting Asthma Biologic Market Size by Type (2021-2026)
5.3 Americas Long-Acting Asthma Biologic Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-Acting Asthma Biologic Market Size by Region (2021-2026)
6.2 APAC Long-Acting Asthma Biologic Market Size by Type (2021-2026)
6.3 APAC Long-Acting Asthma Biologic Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Long-Acting Asthma Biologic Market Size by Country (2021-2026)
7.2 Europe Long-Acting Asthma Biologic Market Size by Type (2021-2026)
7.3 Europe Long-Acting Asthma Biologic Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-Acting Asthma Biologic by Region (2021-2026)
8.2 Middle East & Africa Long-Acting Asthma Biologic Market Size by Type (2021-2026)
8.3 Middle East & Africa Long-Acting Asthma Biologic Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL LONG-ACTING ASTHMA BIOLOGIC MARKET FORECAST
10.1 Global Long-Acting Asthma Biologic Forecast by Region (2027-2032)
10.1.1 Global Long-Acting Asthma Biologic Forecast by Region (2027-2032)
10.1.2 Americas Long-Acting Asthma Biologic Forecast
10.1.3 APAC Long-Acting Asthma Biologic Forecast
10.1.4 Europe Long-Acting Asthma Biologic Forecast
10.1.5 Middle East & Africa Long-Acting Asthma Biologic Forecast
10.2 Americas Long-Acting Asthma Biologic Forecast by Country (2027-2032)
10.2.1 United States Market Long-Acting Asthma Biologic Forecast
10.2.2 Canada Market Long-Acting Asthma Biologic Forecast
10.2.3 Mexico Market Long-Acting Asthma Biologic Forecast
10.2.4 Brazil Market Long-Acting Asthma Biologic Forecast
10.3 APAC Long-Acting Asthma Biologic Forecast by Region (2027-2032)
10.3.1 China Long-Acting Asthma Biologic Market Forecast
10.3.2 Japan Market Long-Acting Asthma Biologic Forecast
10.3.3 Korea Market Long-Acting Asthma Biologic Forecast
10.3.4 Southeast Asia Market Long-Acting Asthma Biologic Forecast
10.3.5 India Market Long-Acting Asthma Biologic Forecast
10.3.6 Australia Market Long-Acting Asthma Biologic Forecast
10.4 Europe Long-Acting Asthma Biologic Forecast by Country (2027-2032)
10.4.1 Germany Market Long-Acting Asthma Biologic Forecast
10.4.2 France Market Long-Acting Asthma Biologic Forecast
10.4.3 UK Market Long-Acting Asthma Biologic Forecast
10.4.4 Italy Market Long-Acting Asthma Biologic Forecast
10.4.5 Russia Market Long-Acting Asthma Biologic Forecast
10.5 Middle East & Africa Long-Acting Asthma Biologic Forecast by Region (2027-2032)
10.5.1 Egypt Market Long-Acting Asthma Biologic Forecast
10.5.2 South Africa Market Long-Acting Asthma Biologic Forecast
10.5.3 Israel Market Long-Acting Asthma Biologic Forecast
10.5.4 Turkey Market Long-Acting Asthma Biologic Forecast
10.6 Global Long-Acting Asthma Biologic Forecast by Type (2027-2032)
10.7 Global Long-Acting Asthma Biologic Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Long-Acting Asthma Biologic Forecast
11 KEY PLAYERS ANALYSIS
11.1 GSK
11.1.1 GSK Company Information
11.1.2 GSK Long-Acting Asthma Biologic Product Offered
11.1.3 GSK Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 GSK Main Business Overview
11.1.5 GSK Latest Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Long-Acting Asthma Biologic Product Offered
11.2.3 AstraZeneca Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 AstraZeneca Main Business Overview
11.2.5 AstraZeneca Latest Developments
11.3 Amgen
11.3.1 Amgen Company Information
11.3.2 Amgen Long-Acting Asthma Biologic Product Offered
11.3.3 Amgen Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Amgen Main Business Overview
11.3.5 Amgen Latest Developments
11.4 Novartis
11.4.1 Novartis Company Information
11.4.2 Novartis Long-Acting Asthma Biologic Product Offered
11.4.3 Novartis Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Novartis Main Business Overview
11.4.5 Novartis Latest Developments
11.5 Roche Holding
11.5.1 Roche Holding Company Information
11.5.2 Roche Holding Long-Acting Asthma Biologic Product Offered
11.5.3 Roche Holding Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Roche Holding Main Business Overview
11.5.5 Roche Holding Latest Developments
11.6 Sanofi
11.6.1 Sanofi Company Information
11.6.2 Sanofi Long-Acting Asthma Biologic Product Offered
11.6.3 Sanofi Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sanofi Main Business Overview
11.6.5 Sanofi Latest Developments
11.7 Regeneron Pharmaceuticals
11.7.1 Regeneron Pharmaceuticals Company Information
11.7.2 Regeneron Pharmaceuticals Long-Acting Asthma Biologic Product Offered
11.7.3 Regeneron Pharmaceuticals Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Regeneron Pharmaceuticals Main Business Overview
11.7.5 Regeneron Pharmaceuticals Latest Developments
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Company Information
11.8.2 Teva Pharmaceutical Long-Acting Asthma Biologic Product Offered
11.8.3 Teva Pharmaceutical Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Teva Pharmaceutical Main Business Overview
11.8.5 Teva Pharmaceutical Latest Developments
11.9 Mabpharm Limited
11.9.1 Mabpharm Limited Company Information
11.9.2 Mabpharm Limited Long-Acting Asthma Biologic Product Offered
11.9.3 Mabpharm Limited Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Mabpharm Limited Main Business Overview
11.9.5 Mabpharm Limited Latest Developments
11.10 CSPC Pharmaceutical
11.10.1 CSPC Pharmaceutical Company Information
11.10.2 CSPC Pharmaceutical Long-Acting Asthma Biologic Product Offered
11.10.3 CSPC Pharmaceutical Long-Acting Asthma Biologic Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 CSPC Pharmaceutical Main Business Overview
11.10.5 CSPC Pharmaceutical Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Long-Acting Asthma Biologic Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Long-Acting Asthma Biologic Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Ultra-Long-Acting Biologics
Table 4. Major Players of Long-Interval Biologics
Table 5. Major Players of Monthly Biologics
Table 6. Long-Acting Asthma Biologic Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Long-Acting Asthma Biologic Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
Table 9. Major Players of Anti-IL-5 Biologics
Table 10. Major Players of Anti-IL-5R? Biologics
Table 11. Major Players of Anti-IgE Biologics
Table 12. Major Players of Anti-IL-4R? Biologics
Table 13. Major Players of Anti-TSLP Biologics
Table 14. Long-Acting Asthma Biologic Market Size CAGR by Antibody Types (2021 VS 2025 VS 2032) & ($ millions)
Table 15. Global Long-Acting Asthma Biologic Market Size by Antibody Types (2021-2026) & ($ millions)
Table 16. Global Long-Acting Asthma Biologic Market Size Market Share by Antibody Types (2021-2026)
Table 17. Major Players of Depemokimab
Table 18. Major Players of Benralizumab
Table 19. Major Players of Mepolizumab
Table 20. Major Players of Reslizumab
Table 21. Major Players of Tezepelumab
Table 22. Major Players of Omalizumab
Table 23. Major Players of Dupilumab
Table 24. Long-Acting Asthma Biologic Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032) & ($ millions)
Table 25. Global Long-Acting Asthma Biologic Market Size by Drugs Type (2021-2026) & ($ millions)
Table 26. Global Long-Acting Asthma Biologic Market Size Market Share by Drugs Type (2021-2026)
Table 27. Long-Acting Asthma Biologic Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 28. Global Long-Acting Asthma Biologic Market Size by Application (2021-2026) & ($ millions)
Table 29. Global Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
Table 30. Global Long-Acting Asthma Biologic Revenue by Player (2021-2026) & ($ millions)
Table 31. Global Long-Acting Asthma Biologic Revenue Market Share by Player (2021-2026)
Table 32. Long-Acting Asthma Biologic Key Players Head office and Products Offered
Table 33. Long-Acting Asthma Biologic Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 34. New Products and Potential Entrants
Table 35. Mergers & Acquisitions, Expansion
Table 36. Global Long-Acting Asthma Biologic Market Size by Region (2021-2026) & ($ millions)
Table 37. Global Long-Acting Asthma Biologic Market Size Market Share by Region (2021-2026)
Table 38. Global Long-Acting Asthma Biologic Revenue by Country/Region (2021-2026) & ($ millions)
Table 39. Global Long-Acting Asthma Biologic Revenue Market Share by Country/Region (2021-2026)
Table 40. Americas Long-Acting Asthma Biologic Market Size by Country (2021-2026) & ($ millions)
Table 41. Americas Long-Acting Asthma Biologic Market Size Market Share by Country (2021-2026)
Table 42. Americas Long-Acting Asthma Biologic Market Size by Type (2021-2026) & ($ millions)
Table 43. Americas Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
Table 44. Americas Long-Acting Asthma Biologic Market Size by Application (2021-2026) & ($ millions)
Table 45. Americas Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
Table 46. APAC Long-Acting Asthma Biologic Market Size by Region (2021-2026) & ($ millions)
Table 47. APAC Long-Acting Asthma Biologic Market Size Market Share by Region (2021-2026)
Table 48. APAC Long-Acting Asthma Biologic Market Size by Type (2021-2026) & ($ millions)
Table 49. APAC Long-Acting Asthma Biologic Market Size by Application (2021-2026) & ($ millions)
Table 50. Europe Long-Acting Asthma Biologic Market Size by Country (2021-2026) & ($ millions)
Table 51. Europe Long-Acting Asthma Biologic Market Size Market Share by Country (2021-2026)
Table 52. Europe Long-Acting Asthma Biologic Market Size by Type (2021-2026) & ($ millions)
Table 53. Europe Long-Acting Asthma Biologic Market Size by Application (2021-2026) & ($ millions)
Table 54. Middle East & Africa Long-Acting Asthma Biologic Market Size by Region (2021-2026) & ($ millions)
Table 55. Middle East & Africa Long-Acting Asthma Biologic Market Size by Type (2021-2026) & ($ millions)
Table 56. Middle East & Africa Long-Acting Asthma Biologic Market Size by Application (2021-2026) & ($ millions)
Table 57. Key Market Drivers & Growth Opportunities of Long-Acting Asthma Biologic
Table 58. Key Market Challenges & Risks of Long-Acting Asthma Biologic
Table 59. Key Industry Trends of Long-Acting Asthma Biologic
Table 60. Global Long-Acting Asthma Biologic Market Size Forecast by Region (2027-2032) & ($ millions)
Table 61. Global Long-Acting Asthma Biologic Market Size Market Share Forecast by Region (2027-2032)
Table 62. Global Long-Acting Asthma Biologic Market Size Forecast by Type (2027-2032) & ($ millions)
Table 63. Global Long-Acting Asthma Biologic Market Size Forecast by Application (2027-2032) & ($ millions)
Table 64. GSK Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 65. GSK Long-Acting Asthma Biologic Product Offered
Table 66. GSK Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. GSK Main Business
Table 68. GSK Latest Developments
Table 69. AstraZeneca Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 70. AstraZeneca Long-Acting Asthma Biologic Product Offered
Table 71. AstraZeneca Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. AstraZeneca Main Business
Table 73. AstraZeneca Latest Developments
Table 74. Amgen Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 75. Amgen Long-Acting Asthma Biologic Product Offered
Table 76. Amgen Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Amgen Main Business
Table 78. Amgen Latest Developments
Table 79. Novartis Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 80. Novartis Long-Acting Asthma Biologic Product Offered
Table 81. Novartis Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. Novartis Main Business
Table 83. Novartis Latest Developments
Table 84. Roche Holding Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 85. Roche Holding Long-Acting Asthma Biologic Product Offered
Table 86. Roche Holding Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. Roche Holding Main Business
Table 88. Roche Holding Latest Developments
Table 89. Sanofi Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 90. Sanofi Long-Acting Asthma Biologic Product Offered
Table 91. Sanofi Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. Sanofi Main Business
Table 93. Sanofi Latest Developments
Table 94. Regeneron Pharmaceuticals Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 95. Regeneron Pharmaceuticals Long-Acting Asthma Biologic Product Offered
Table 96. Regeneron Pharmaceuticals Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. Regeneron Pharmaceuticals Main Business
Table 98. Regeneron Pharmaceuticals Latest Developments
Table 99. Teva Pharmaceutical Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 100. Teva Pharmaceutical Long-Acting Asthma Biologic Product Offered
Table 101. Teva Pharmaceutical Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. Teva Pharmaceutical Main Business
Table 103. Teva Pharmaceutical Latest Developments
Table 104. Mabpharm Limited Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 105. Mabpharm Limited Long-Acting Asthma Biologic Product Offered
Table 106. Mabpharm Limited Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. Mabpharm Limited Main Business
Table 108. Mabpharm Limited Latest Developments
Table 109. CSPC Pharmaceutical Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 110. CSPC Pharmaceutical Long-Acting Asthma Biologic Product Offered
Table 111. CSPC Pharmaceutical Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. CSPC Pharmaceutical Main Business
Table 113. CSPC Pharmaceutical Latest Developments
Table 1. Long-Acting Asthma Biologic Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Long-Acting Asthma Biologic Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Ultra-Long-Acting Biologics
Table 4. Major Players of Long-Interval Biologics
Table 5. Major Players of Monthly Biologics
Table 6. Long-Acting Asthma Biologic Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Long-Acting Asthma Biologic Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
Table 9. Major Players of Anti-IL-5 Biologics
Table 10. Major Players of Anti-IL-5R? Biologics
Table 11. Major Players of Anti-IgE Biologics
Table 12. Major Players of Anti-IL-4R? Biologics
Table 13. Major Players of Anti-TSLP Biologics
Table 14. Long-Acting Asthma Biologic Market Size CAGR by Antibody Types (2021 VS 2025 VS 2032) & ($ millions)
Table 15. Global Long-Acting Asthma Biologic Market Size by Antibody Types (2021-2026) & ($ millions)
Table 16. Global Long-Acting Asthma Biologic Market Size Market Share by Antibody Types (2021-2026)
Table 17. Major Players of Depemokimab
Table 18. Major Players of Benralizumab
Table 19. Major Players of Mepolizumab
Table 20. Major Players of Reslizumab
Table 21. Major Players of Tezepelumab
Table 22. Major Players of Omalizumab
Table 23. Major Players of Dupilumab
Table 24. Long-Acting Asthma Biologic Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032) & ($ millions)
Table 25. Global Long-Acting Asthma Biologic Market Size by Drugs Type (2021-2026) & ($ millions)
Table 26. Global Long-Acting Asthma Biologic Market Size Market Share by Drugs Type (2021-2026)
Table 27. Long-Acting Asthma Biologic Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 28. Global Long-Acting Asthma Biologic Market Size by Application (2021-2026) & ($ millions)
Table 29. Global Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
Table 30. Global Long-Acting Asthma Biologic Revenue by Player (2021-2026) & ($ millions)
Table 31. Global Long-Acting Asthma Biologic Revenue Market Share by Player (2021-2026)
Table 32. Long-Acting Asthma Biologic Key Players Head office and Products Offered
Table 33. Long-Acting Asthma Biologic Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 34. New Products and Potential Entrants
Table 35. Mergers & Acquisitions, Expansion
Table 36. Global Long-Acting Asthma Biologic Market Size by Region (2021-2026) & ($ millions)
Table 37. Global Long-Acting Asthma Biologic Market Size Market Share by Region (2021-2026)
Table 38. Global Long-Acting Asthma Biologic Revenue by Country/Region (2021-2026) & ($ millions)
Table 39. Global Long-Acting Asthma Biologic Revenue Market Share by Country/Region (2021-2026)
Table 40. Americas Long-Acting Asthma Biologic Market Size by Country (2021-2026) & ($ millions)
Table 41. Americas Long-Acting Asthma Biologic Market Size Market Share by Country (2021-2026)
Table 42. Americas Long-Acting Asthma Biologic Market Size by Type (2021-2026) & ($ millions)
Table 43. Americas Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
Table 44. Americas Long-Acting Asthma Biologic Market Size by Application (2021-2026) & ($ millions)
Table 45. Americas Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
Table 46. APAC Long-Acting Asthma Biologic Market Size by Region (2021-2026) & ($ millions)
Table 47. APAC Long-Acting Asthma Biologic Market Size Market Share by Region (2021-2026)
Table 48. APAC Long-Acting Asthma Biologic Market Size by Type (2021-2026) & ($ millions)
Table 49. APAC Long-Acting Asthma Biologic Market Size by Application (2021-2026) & ($ millions)
Table 50. Europe Long-Acting Asthma Biologic Market Size by Country (2021-2026) & ($ millions)
Table 51. Europe Long-Acting Asthma Biologic Market Size Market Share by Country (2021-2026)
Table 52. Europe Long-Acting Asthma Biologic Market Size by Type (2021-2026) & ($ millions)
Table 53. Europe Long-Acting Asthma Biologic Market Size by Application (2021-2026) & ($ millions)
Table 54. Middle East & Africa Long-Acting Asthma Biologic Market Size by Region (2021-2026) & ($ millions)
Table 55. Middle East & Africa Long-Acting Asthma Biologic Market Size by Type (2021-2026) & ($ millions)
Table 56. Middle East & Africa Long-Acting Asthma Biologic Market Size by Application (2021-2026) & ($ millions)
Table 57. Key Market Drivers & Growth Opportunities of Long-Acting Asthma Biologic
Table 58. Key Market Challenges & Risks of Long-Acting Asthma Biologic
Table 59. Key Industry Trends of Long-Acting Asthma Biologic
Table 60. Global Long-Acting Asthma Biologic Market Size Forecast by Region (2027-2032) & ($ millions)
Table 61. Global Long-Acting Asthma Biologic Market Size Market Share Forecast by Region (2027-2032)
Table 62. Global Long-Acting Asthma Biologic Market Size Forecast by Type (2027-2032) & ($ millions)
Table 63. Global Long-Acting Asthma Biologic Market Size Forecast by Application (2027-2032) & ($ millions)
Table 64. GSK Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 65. GSK Long-Acting Asthma Biologic Product Offered
Table 66. GSK Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. GSK Main Business
Table 68. GSK Latest Developments
Table 69. AstraZeneca Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 70. AstraZeneca Long-Acting Asthma Biologic Product Offered
Table 71. AstraZeneca Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. AstraZeneca Main Business
Table 73. AstraZeneca Latest Developments
Table 74. Amgen Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 75. Amgen Long-Acting Asthma Biologic Product Offered
Table 76. Amgen Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Amgen Main Business
Table 78. Amgen Latest Developments
Table 79. Novartis Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 80. Novartis Long-Acting Asthma Biologic Product Offered
Table 81. Novartis Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. Novartis Main Business
Table 83. Novartis Latest Developments
Table 84. Roche Holding Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 85. Roche Holding Long-Acting Asthma Biologic Product Offered
Table 86. Roche Holding Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. Roche Holding Main Business
Table 88. Roche Holding Latest Developments
Table 89. Sanofi Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 90. Sanofi Long-Acting Asthma Biologic Product Offered
Table 91. Sanofi Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. Sanofi Main Business
Table 93. Sanofi Latest Developments
Table 94. Regeneron Pharmaceuticals Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 95. Regeneron Pharmaceuticals Long-Acting Asthma Biologic Product Offered
Table 96. Regeneron Pharmaceuticals Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. Regeneron Pharmaceuticals Main Business
Table 98. Regeneron Pharmaceuticals Latest Developments
Table 99. Teva Pharmaceutical Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 100. Teva Pharmaceutical Long-Acting Asthma Biologic Product Offered
Table 101. Teva Pharmaceutical Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. Teva Pharmaceutical Main Business
Table 103. Teva Pharmaceutical Latest Developments
Table 104. Mabpharm Limited Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 105. Mabpharm Limited Long-Acting Asthma Biologic Product Offered
Table 106. Mabpharm Limited Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. Mabpharm Limited Main Business
Table 108. Mabpharm Limited Latest Developments
Table 109. CSPC Pharmaceutical Details, Company Type, Long-Acting Asthma Biologic Area Served and Its Competitors
Table 110. CSPC Pharmaceutical Long-Acting Asthma Biologic Product Offered
Table 111. CSPC Pharmaceutical Long-Acting Asthma Biologic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. CSPC Pharmaceutical Main Business
Table 113. CSPC Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Long-Acting Asthma Biologic Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Long-Acting Asthma Biologic Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Long-Acting Asthma Biologic Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Long-Acting Asthma Biologic Sales Market Share by Country/Region (2025)
Figure 8. Long-Acting Asthma Biologic Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Long-Acting Asthma Biologic Market Size Market Share by Type in 2025
Figure 10. Global Long-Acting Asthma Biologic Market Size Market Share by Antibody Types in 2025
Figure 11. Global Long-Acting Asthma Biologic Market Size Market Share by Drugs Type in 2025
Figure 12. Long-Acting Asthma Biologic in evere Eosinophilic Asthma
Figure 13. Global Long-Acting Asthma Biologic Market: evere Eosinophilic Asthma (2021-2026) & ($ millions)
Figure 14. Long-Acting Asthma Biologic in Moderate-to-Severe Allergic Asthma
Figure 15. Global Long-Acting Asthma Biologic Market: Moderate-to-Severe Allergic Asthma (2021-2026) & ($ millions)
Figure 16. Long-Acting Asthma Biologic in Severe Type 2 Asthma
Figure 17. Global Long-Acting Asthma Biologic Market: Severe Type 2 Asthma (2021-2026) & ($ millions)
Figure 18. Long-Acting Asthma Biologic in Other
Figure 19. Global Long-Acting Asthma Biologic Market: Other (2021-2026) & ($ millions)
Figure 20. Global Long-Acting Asthma Biologic Market Size Market Share by Application in 2025
Figure 21. Global Long-Acting Asthma Biologic Revenue Market Share by Player in 2025
Figure 22. Global Long-Acting Asthma Biologic Market Size Market Share by Region (2021-2026)
Figure 23. Americas Long-Acting Asthma Biologic Market Size 2021-2026 ($ millions)
Figure 24. APAC Long-Acting Asthma Biologic Market Size 2021-2026 ($ millions)
Figure 25. Europe Long-Acting Asthma Biologic Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa Long-Acting Asthma Biologic Market Size 2021-2026 ($ millions)
Figure 27. Americas Long-Acting Asthma Biologic Value Market Share by Country in 2025
Figure 28. United States Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC Long-Acting Asthma Biologic Market Size Market Share by Region in 2025
Figure 33. APAC Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
Figure 34. APAC Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
Figure 35. China Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 39. India Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe Long-Acting Asthma Biologic Market Size Market Share by Country in 2025
Figure 42. Europe Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
Figure 43. Europe Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
Figure 44. Germany Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 45. France Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 46. UK Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa Long-Acting Asthma Biologic Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
Figure 51. Middle East & Africa Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
Figure 52. Egypt Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 58. APAC Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 59. Europe Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 61. United States Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 62. Canada Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 63. Mexico Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 64. Brazil Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 65. China Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 66. Japan Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 67. Korea Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 69. India Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 70. Australia Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 71. Germany Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 72. France Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 73. UK Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 74. Italy Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 75. Russia Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 76. Egypt Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 77. South Africa Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 78. Israel Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 79. Turkey Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 80. Global Long-Acting Asthma Biologic Market Size Market Share Forecast by Type (2027-2032)
Figure 81. Global Long-Acting Asthma Biologic Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 1. Long-Acting Asthma Biologic Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Long-Acting Asthma Biologic Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Long-Acting Asthma Biologic Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Long-Acting Asthma Biologic Sales Market Share by Country/Region (2025)
Figure 8. Long-Acting Asthma Biologic Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Long-Acting Asthma Biologic Market Size Market Share by Type in 2025
Figure 10. Global Long-Acting Asthma Biologic Market Size Market Share by Antibody Types in 2025
Figure 11. Global Long-Acting Asthma Biologic Market Size Market Share by Drugs Type in 2025
Figure 12. Long-Acting Asthma Biologic in evere Eosinophilic Asthma
Figure 13. Global Long-Acting Asthma Biologic Market: evere Eosinophilic Asthma (2021-2026) & ($ millions)
Figure 14. Long-Acting Asthma Biologic in Moderate-to-Severe Allergic Asthma
Figure 15. Global Long-Acting Asthma Biologic Market: Moderate-to-Severe Allergic Asthma (2021-2026) & ($ millions)
Figure 16. Long-Acting Asthma Biologic in Severe Type 2 Asthma
Figure 17. Global Long-Acting Asthma Biologic Market: Severe Type 2 Asthma (2021-2026) & ($ millions)
Figure 18. Long-Acting Asthma Biologic in Other
Figure 19. Global Long-Acting Asthma Biologic Market: Other (2021-2026) & ($ millions)
Figure 20. Global Long-Acting Asthma Biologic Market Size Market Share by Application in 2025
Figure 21. Global Long-Acting Asthma Biologic Revenue Market Share by Player in 2025
Figure 22. Global Long-Acting Asthma Biologic Market Size Market Share by Region (2021-2026)
Figure 23. Americas Long-Acting Asthma Biologic Market Size 2021-2026 ($ millions)
Figure 24. APAC Long-Acting Asthma Biologic Market Size 2021-2026 ($ millions)
Figure 25. Europe Long-Acting Asthma Biologic Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa Long-Acting Asthma Biologic Market Size 2021-2026 ($ millions)
Figure 27. Americas Long-Acting Asthma Biologic Value Market Share by Country in 2025
Figure 28. United States Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC Long-Acting Asthma Biologic Market Size Market Share by Region in 2025
Figure 33. APAC Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
Figure 34. APAC Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
Figure 35. China Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 39. India Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe Long-Acting Asthma Biologic Market Size Market Share by Country in 2025
Figure 42. Europe Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
Figure 43. Europe Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
Figure 44. Germany Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 45. France Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 46. UK Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa Long-Acting Asthma Biologic Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa Long-Acting Asthma Biologic Market Size Market Share by Type (2021-2026)
Figure 51. Middle East & Africa Long-Acting Asthma Biologic Market Size Market Share by Application (2021-2026)
Figure 52. Egypt Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries Long-Acting Asthma Biologic Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 58. APAC Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 59. Europe Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 61. United States Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 62. Canada Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 63. Mexico Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 64. Brazil Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 65. China Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 66. Japan Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 67. Korea Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 69. India Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 70. Australia Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 71. Germany Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 72. France Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 73. UK Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 74. Italy Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 75. Russia Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 76. Egypt Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 77. South Africa Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 78. Israel Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 79. Turkey Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
Figure 80. Global Long-Acting Asthma Biologic Market Size Market Share Forecast by Type (2027-2032)
Figure 81. Global Long-Acting Asthma Biologic Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries Long-Acting Asthma Biologic Market Size 2027-2032 ($ millions)
